GlassScriptPhysician profile
Perla J Andin
NPI 1023013059
$8,576.12
in general payments reported to CMS, 2019-2025
49 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,527 · 2020: $989 · 2021: $851 · 2022: $1,097 · 2023: $710 · 2024: $2,098 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,112.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $929.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $868.71 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $813.69 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $733.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $605.38 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $553.78 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $482.13 | 2022-2025 | Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $415.20 | 2022-2025 | Rexulti, Abilify Maintena |
| Exact Sciences Corporation | $376.67 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $218.64 | 2022-2025 | |
| Medtronic, INC. | $198.81 | 2022-2025 | Minimed 780g |
| Astellas Pharma US INC | $172.29 | 2019-2024 | Veozah |
| Amgen INC. | $167.29 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $152.70 | 2019-2024 | Freestyle Libre |
| Janssen Pharmaceuticals, INC | $150.71 | 2019-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perla Andin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.